Whole body (WB) MRI is developing as a cancer staging platform in primary prostate cancer, although has not yet been adopted into clinical practice. In this study, we show that WB-MRI provides high levels of interobserver concordance, intermodality concordance and diagnostic accuracy for both nodal and metastatic bone disease, with higher levels of sensitivity than BS for metastatic disease, and similar performance to PET/CT. We also show that T2W and post contrast mDixon have no additive diagnostic value above T1W and DWI alone.
This abstract and the presentation materials are available to members only; a login is required.